Latest Conference Articles

“We want to make sure we can provide the right treatment for the right patient at the right time,” says Olufunmilayo I. Olopade, MD, FACP, OON.

With a newfound abundance of available oral cancer therapies, it has become necessary for oncology nurses to ensure that their patients are adhering to treatment.

Teresa Knoop, MSN, RN, AOCN, says it is important for oncology nurses to understand the naming convention of biosimilars as it is an important aspect of anticipating adverse events.

Beth Sandy, MSN, CRNP, OCN, says that she would like to see 95% of eligible patients receive biomarker testing in the next 5 to 10 years.

Preliminary study results recently presented at the 2021 European Association of Urology Congress demonstrate that the safety profile of the combination of Bacillus Calmette-Guérin (BCG) and mitomycin is comparable to BCG alone.

ASCO updated its guidelines following a presentation of the OlympiA trial presented at its 2021 Annual Meeting.

A presentation at the 2021 American Society of Clinical Oncology Meeting demonstrated that the use of electronic patient-reported outcomes in community oncology centers improved symptom-management.

Data from the phase 3 JUPITER-02 trial (NCT03581786) suggests that frontline toripalimab plus gemcitabine/cisplatin improves progression-free survival (PFS).

Survival outcomes in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma were improved when nivolumab was added alongside either ipilimumab or chemotherapy.

KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.

Cabozantinib exposure was not a predictor of progression-free survival was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma.

This year, there were many takeaways from the American Society of Clinical Oncology Annual Meeting that oncology nurses can incorporate into their practice.

Learn how to approach palliative care discussions with both physicians and patients.

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.

Pralsetinib elicited promising responses and tolerability in patients with RET fusion-positive non-small cell lung cancer (NSCLC), including those who were not eligible for platinum-based therapy.

Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.

States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research.

When in-person classes on central venous catheter care were limited due to the COVID-19 pandemic, educational videos became even more important.

Knowing your patient’s beliefs and goals is key to providing ethical cancer care.

Nurse practitioners are more valuable than ever in the world of cancer care.

Factors such as being younger in age, having more comorbidities, and more prior cancer treatments all contribute to higher levels of sleep disturbance in patients with gastrointestinal cancers.

In particular, patients reported improved knowledge in survivorship/surveillance and brain fog following the 6-week program.